Marilina Amabile - Concepedia

Author

Marilina Amabile

University of Bologna ORCID

Also Known As

M AMABILE, M Amabile, M. AMABILE, M. Amabile, Marilina Amabile, Marina Amabile, Simona Soverini

171

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

University of Bologna University of Turin Sapienza University of Rome University of Naples Federico II IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola

About

Marilina Amabile is an author at University of Bologna specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	906
2	Health Sciences	8	8	525
3	Engineering	2	2	80
4	Allergy	1	1	101
5	Biomedical Engineering	1	1	34

Marilina Amabile

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia Simona Soverini, Sabrina Colarossi, Alessandra Gnani, Clinical Cancer Research	2006	510
ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia Simona Soverini, Giovanni Martinelli, Gianantonio Rosti, Journal of Clinical Oncology	2005	372
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial Monica Bocchia, S Gentili, Elisabetta Abruzzese, The Lancet VaccinationHematological MalignancyChronic Myeloid LeukaemiaMedicineHematology	2005	230
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia Gianantonio Rosti, Francesca Palandri, Fausto Castagnetti, Blood	2009	210
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells Alessandra Fortuna, MR Motta, Simonetta Rizzi, Blood	1996	178
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors Simona Soverini, Alessandra Gnani, Sabrina Colarossi, Blood	2009	173
Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma Giovanni Martinelli, Carolina Terragna, Elena Zamagni, Journal of Clinical Oncology	2000	170
A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia Michele Baccarani, Gianantonio Rosti, Antonio De Vivo, Blood	2002	167
Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state Silvia Buonamici, Emanuela Ottaviani, Nicoletta Testoni, Blood	2002	152
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial Monica Bocchia, S Gentili, Elisabetta Abruzzese, The Lancet VaccinationHematological MalignancyChronic Myeloid LeukaemiaMedicineHematology	2005	135

Page 1